drugset
drugset / Trial / NCT00101985

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985 ↗

Phase 2 Completed 741 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).

Timeline

Start
2004-10
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject talnetant Small molecule — —

Indications

irritable bowel syndrome